A comprehensive survey by Instituto Karolinska scientists at Suécia has consolidated evidence on the long-term effectiveness of human papillomavirus (HPV) vaccination. The data, which cover almost two decades of follow-up, indicate that immunization carried out during adolescence is capable of reducing the risk of developing invasive cervical cancer by up to 79%. The research monitored the health of more than 900,000 women, offering one of the most detailed overviews ever produced of the real impact of the vaccine on public health.
The study followed the clinical evolution of the participants between 2006 and 2023, cross-referencing information from national health records to ensure the accuracy of diagnoses. The analysis focused on the quadrivalent vaccine, a formulation that protects against four types of the virus, including the most aggressive oncogenic variants responsible for the majority of malignant tumors in this anatomical region.
The results point to sustained protection, with no signs of decline in immunity even after 18 years of applying the doses. Especialistas highlight that this durability is fundamental for strategies to eradicate the disease, as it currently eliminates the need for booster doses in adulthood for those who were correctly immunized in their youth.
In addition to the drop in cases of invasive cancer, a robust reduction in precursor lesions, known as CIN2 and CIN3, was observed. The epidemiological scenario designed by the research reinforces the importance of adhering to vaccination schedules before starting sexual life, a period in which the body’s immune response appears to be more vigorous and effective in preventing viral infection.
Proven effectiveness in different age groups
Swedish research has established a direct correlation between the age of vaccination and the level of protection acquired throughout adult life. Mulheres who received the vaccine before the age of 17 had the best clinical outcomes, with the incidence of the disease falling to residual levels. In contrast, the unvaccinated group maintained significantly higher diagnosis rates, following historical disease patterns.
For women immunized between 17 and 30 years old, the benefits were also confirmed, although at different levels. Houve a 37% reduction in the overall risk of cervical cancer, a number that progressively improves as post-vaccination time progresses. Isso suggests that, even late, the vaccine plays a crucial role in mitigating risks, although the priority strategy should focus on younger age groups.
The study detailed the following points about immune response and risk reduction:
- Protection against invasive cancer reached 79% in women vaccinated before the age of 17.
- There was no evidence of weakening of the immune defense after 15 years of application.
- The incidence of tumors fell drastically in cohorts born after 1999, which had easier access to the vaccine.
- Late immunization (after age 17) still offers significant protection, halving the risk after a decade.
Sustainability of immune protection
One of the most relevant findings from the monitoring was the stability of the immune response. Unlike other vaccines that require periodic boosters, the HPV vaccine has been shown to maintain its effectiveness unchanged for nearly two decades. The researchers found no increase in the rate of vaccine failures or the emergence of serious cases among those vaccinated as they aged.
This characteristic has direct implications for the management of health resources. Confirming that protection is lasting allows governments to focus their budgets on expanding primary coverage, seeking to reach girls and boys who have not yet been vaccinated, instead of spending on revaccination of already protected adults.
The absence of a decline in immunity validates the current guidelines of Organização Mundial of the Saúde (WHO), which recommends focusing on immunization of children and adolescents between 9 and 14 years of age. The Swedish model now serves as a real-time proof of concept, demonstrating that eliminating cervical cancer is an achievable goal through consistent public policies.
Impact on health and prevention systems
The significant reduction in the number of cancer cases relieves pressure on healthcare systems, reducing the need for complex treatments such as surgery, radiotherapy and chemotherapy. The study showed that, in groups with high vaccination coverage, the disease became rare, transforming the epidemiological profile of a condition that was previously one of the main causes of female mortality.
In addition to preventing cancer, the vaccine proved to be effective in reducing invasive diagnostic procedures. With fewer suspicious lesions appearing on screening tests, fewer women need to undergo biopsies and conizations, procedures that can have impacts on future reproductive health, such as increasing the risk of premature births.
Global context and comparative data
Although the study was carried out in Suécia, its results speak directly to the reality of other countries, including Brasil. National Pesquisas and data from Ministério from
In Escócia, similar data were observed, with the almost eradication of the disease in women born after 1995. The convergence of results in different populations and health systems reinforces that the vaccine is a universally effective tool, regardless of local genetic or environmental variations, as long as vaccination coverage is broad.
The remaining challenge is compliance. In many regions, coverage is still below the 90% target set by the WHO. Combating misinformation and ensuring access in schools are cited by experts as critical next steps to replicating Sweden’s success on a global scale.
Future perspectives for eradication
With the confirmation that the vaccine protects for decades and prevents the vast majority of serious cases, the scientific community sees the real possibility of eradicating cervical cancer as a public health problem within this century. The combination of high vaccination coverage with high-precision screening tests (HPV DNA tests) forms the gold standard of modern prevention.
The Instituto Karolinska researchers emphasize that monitoring will continue, seeking to understand whether the protection extends throughout life. However, current data is already sufficient to classify HPV vaccination as one of the most successful health interventions of recent decades, with the potential to save millions of lives globally.
